• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Dual pathway inhibition for atherosclerotic cardiovascular disease: Recent advances
Kardiol Pol. 2022;80(12):1200-1210. doi: 10.33963/KP.a2022.0283.ABSTRACTAtherosclerotic cardiovascular disease (ASCVD), which includes coronary artery disease (CAD), cerebrovascular disease, and peripheral arterial disease (PAD) is associated with significant morbidity, mortality, and healthcare costs. Antiplatelet therapy has long been the mainstay of antithrombotic therapy for the prevention of first-ever and recurrent ASCVD events. More recently, however, randomized trials have demonstrated the benefits and cost-effectiveness of a dual pathway inhibition (DPI) strategy in acute and chronic ASCVD. When used in combinatio...
Source: Polish Heart Journal - January 5, 2023 Category: Cardiology Authors: Stephanie Carlin Tim Ac de Vries Andrzej Budaj John Eikelboom Source Type: research

Dual antiplatelet therapy is safe and efficient after left atrial appendage closure.
CONCLUSIONS: LAAC followed by DAPT seems to be a safe and efficient alternative for stroke prevention in patients with NVAF and contraindications to anticoagulation therapy. This strategy may provide a significant reduction of events such as stroke and bleeding versus the score-predicted rate. PMID: 29350390 [PubMed - as supplied by publisher]
Source: Polish Heart Journal - January 19, 2018 Category: Cardiology Authors: Maksym J, Mazurek T, Kochman J, Grygier M, Kapłon-Cieślicka A, Marchel M, Lodziński P, Piątkowski R, Wilimski R, Czub P, Fojt A, Karolczak N, Hendzel P, Opolski G Tags: Kardiol Pol Source Type: research